- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00367536
Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution
An Open-label, Single-dose, Randomized-to-sequence, 4-period Crossover Bioavailability Study of Bazedoxifene Contained in Bazedoxifene/Conjugated Estrogen Tablets Administered to Healthy Postmenopausal Women.
This study involves the experimental drug bazedoxifene acetate/conjugated estrogens (also called BZA/CE). This drug is not approved by the Food and Drug Administration (FDA).
About 24 subjects will take part in this study. Each subject's participation in this study will last for about 10 weeks. During this study, each subject will receive 3 different types of BZA/CE tablets plus an oral solution containing only BZA. The purpose of this study is to learn how the tablet dosage forms dissolve and are absorbed by the body compared to the BZA oral solution. In addition, information will also be learned about the safety and tolerability of these dosage forms given to healthy postmenopausal women.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Generally healthy, nonsmoking (or smoker of less than 10 cigarettes/day)
- Postmenopausal women aged 35 to 70 years
- At least 12 months of spontaneous amenorrhea, OR 6 months of spontaneous amenorrhea with follicle-stimulating hormone (FSH) levels at least 38 mIU/mL
- Women 55 years of older must have at least 12 months of amenorrhea
- Body mass index in the range of 18.0 to 35.0, with a minimum body weight of 50 kg
Exclusion Criteria:
- A history or active presence of clinically important medical disease.
- History or alcoholism or drug abuse within 1 year before study start.
- Use of estrogen-, androgen-, or progestin-containing medication by a non-oral route of administration within 6 months before study day 1 must be approved by Wyeth Research
Study Plan
How is the study designed?
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3115A1-115
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postmenopause
-
Merck Sharp & Dohme LLCCompleted
-
Wageningen UniversityCompleted
-
Wageningen UniversityCompleted
-
Tel-Aviv Sourasky Medical CenterAmorphical Ltd.Unknown
-
Wyeth is now a wholly owned subsidiary of PfizerMDS Pharma ServicesCompletedPostmenopauseUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPostmenopause
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPostmenopauseUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPostmenopauseUnited States
-
Rene RizzoliCompleted
Clinical Trials on bazedoxifene/conjugated estrogens combination tablet
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Carol Fabian, MDBreast Cancer Research FoundationTerminatedFocus of Study is Healthy Women at Risk for Breast CancerUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPostmenopauseUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPostmenopause
-
Tulane University Health Sciences CenterCompletedObesity | Glucose Homeostasis | Postmenopausal SymptomsUnited States
-
University of Kansas Medical CenterPfizerCompletedBreast CancerUnited States